Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Price, News & Analysis

ARCA biopharma logo

About ARCA biopharma Stock (NASDAQ:ABIO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.40
$599.04
52-Week Range
N/A
Volume
290,800 shs
Average Volume
607,995 shs
Market Capitalization
$34.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

Only a handful of people know the setup that's defied these chaotic markets.
Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…
FMR LLC Acquires New Stake in ARCA biopharma Inc
See More Headlines

ABIO Stock Analysis - Frequently Asked Questions

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) EPS for the quarter, topping the consensus estimate of ($341.28) by $292.32.

ARCA biopharma's stock reverse split on Tuesday, September 3rd 2024. The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/04/2021
Today
5/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABIO
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.25 per share
Price / Book
N/A

Miscellaneous

Free Float
10,024,000
Market Cap
$34.82 million
Optionable
Optionable
Beta
0.91
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:ABIO) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners